We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

Luminex logo
March 5, 2021

Luminex has been given Emergency Use Authorization (EUA) from the FDA for an expanded version of its NxTAG Respiratory Pathogen Panel, authorizing its use in testing for COVID-19 infection.

The multiplex, high-throughput test is designed to simultaneously detect the most common respiratory pathogens. The new version of the test includes 19 viral and two bacterial targets, including SARS-CoV-2. Significantly, the company said the test is expected to detect new coronavirus variants, including the UK, South African and Brazilian strains, as well as a variant first found in California.

The test allows clinical labs to run up to 96 samples at a time, producing results in approximately four hours. It runs on Luminex’s MAGPIX system and is designed to be used in high-complexity molecular laboratories.

View today's stories

Medical Devices COVID-19 Submissions and Approvals
  • Related Events

    Audits in the World of COVID-19 and Beyond: Are You Ready for Remote Audits?

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Novavax logo

    Novavax Admits Supply Shortages Will Delay Vaccine Production

  • Masimo’s Portable Carbon Dioxide Monitor Gets FDA Clearance

  • EMA logo European Medicines Agency logo

    EMA Reviews GSK’s and Vir’s VIR-7831 for COVID-19

  • CE mark

    Hensler Surgical Technologies Earns CE Mark for Bone-Fusion Device

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing